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Abstract
Current artificial vein grafts for long-term dialysis and
bypass surgeries suffer from atherosclerosis and restenosis, and
they tend to thrombose after initial patient recovery. The
alternative materials, coatings, and polymer interfaces being
explored in stents may be useful in graft applications, increasing
both the quantity and quality of the patient’s life. To better
comprehend the clinical standards and developing alternatives, I
collected previously identified physical and chemical venous
properties, as well as the corresponding synthetic materials that
would support them. I compiled studies of primary and
secondary endpoints (such as death, myocardial infarction,
thrombosis, and target-lesion revascularization) in various graft
materials, polymer coatings, and drugs to gauge efficacy. Based
on my findings, I suggest that everolimus coatings linked to
polytetrafluoroethylene (PTFE) grafts by poly(n-butyl
methcrylate) (PBM) should be subjected to further clinical
research and in-vivo trials.

Introduction
Modern artificial graft options evolved over time from much
simpler designs. The first attempts at artificial vein grafts began
in the 1930s with Dupont, who created a thin-walled, carbon
coated and pre-cuffed graft made out of polytetrafluoroethylene
(PTFE)[1]. It was made in a ringed configuration with a porous
structure. It essentially looked like a small plastic tube. In 1950,
DuPont manufactured a polyethylene terephthalate vascular
implant that had to be pre-clotted. The fabric was woven, and it
used collagen or albumin, which are used today. Gortex was
also developed, which contained heparin that lasted for more
than 230 days in vivo. Later, in 2004, this was proven by Dr. P.
Lin in the Journal of Vascular Surgery to reduce neointimal
hyperplasia. Most recently, polyurethane grafts have been
proven to be more effective then the alternative materials,
though they may be carcinogenic.
In 1995, about 50% of vein grafts failed within 10 years
due to neointimal hyperplasia, or the closing of the vein from
the inside by the buildup of plaque, cholesterol, and other
particles found in the blood[1]. When this happens, smooth
muscle cells (SMC) line the inside of the graft in response to
stress from the surgery or shear stress from blood flow. These
cells quickly buildup and are extremely prone to
atherosclerosis. When this happens, a temporary fix is balloon
angioplasty, in which a catheter is inserted to the site of

of blockage, and then a balloon expands to widen the vein and push the plaque to
the outside of the vein. A filter basket is placed downstream from the balloon to
catch any debris that may have been knocked loose. In cases of more severe
atherosclerosis, however, this is not possible.
Ideally, engineered endothelial cells could be added to the graft, but that would
require overcoming several technological and biological barriers: finding the
problem genes, inserting the replacement genes into the endothelial cells without
stimulating an immune response, culturing those cells, and attaching the cells to the
grafts. Instead, engineering the exterior and then adding a coating would be much
easier. According to the Duke Department of Vascular Surgery, the ideal graft
would allow a flow rate of 500 mL/min, resist infection, not cause an immune
system response, and be inserted easily. Furthermore, the graft access should not
have weeping, be easily clipped, resist infection, and be revised if need be [2].

Materials/Methods
To better comprehend the clinical standards and developing alternatives, I collected
previously identified physical and chemical venous properties, as well as the
corresponding synthetic materials that would support them. I compiled studies of
primary and secondary endpoints (such as death, myocardial infarction, thrombosis,
and target-lesion revascularization) in various graft materials, polymer coatings, and
drugs to gauge efficacy.
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Discussion/Conclusion
Based on my research so far, the tentative answer to my
research question is that everolimus coatings linked to
polytetrafluoroethylene (PTFE) grafts by poly(n-butyl
methacrylate) (PBMA) should be subjected to further clinical
research and in-vivo trials. I think the authors who advocate for
PTFE grafts have stronger studies with more conclusive
evidence, especially compared to those who like resorbable
models. The main point of contention exists in the type of drug
that could be added to make a composite graft, as well as the
nature of the polymer that would anchor it. I think most
scientists realize that the future of grafts lies in bio-absorbable
polymers, but more improvements need to be made in the mean
time since current models are not completely safe and elude too
quickly. As of right now, cobalt and chromium PTFE grafts are
the most successful in people without risk of heart attack,
everolimus is the best drug, and PBMA is the most effective
polymer.

References
http://www.oxford174.com/wp-content/uploads/2014/04/Artery-and-vein.png

Results
In comparisons between various vein graft exteriors, polymers, and drugs,
polytetrafluoroethylene (PTFE) grafts lasted the longest, everolimus was the drug
that decreased primary endpoint failure the most, and poly(n-butyl methacrylate)
(PBMA) acted as the most efficient interface. The only caveats in this combination
is that PTFE is still being investigated as a carcinogen, and that everolimus may
increase the risk of myocardial infarction, or heart attack. The next best alternative
is sirolimus, which has been widely used since the early 2000s and is anchored by
poly(n-butyl methacrylate) (PBMA) and poly(ethylene-co-vinyl acetate) (PEVA).
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